CN106822907B - Two-phase release preparation containing racecadotril and preparation method thereof - Google Patents
Two-phase release preparation containing racecadotril and preparation method thereof Download PDFInfo
- Publication number
- CN106822907B CN106822907B CN201611240544.0A CN201611240544A CN106822907B CN 106822907 B CN106822907 B CN 106822907B CN 201611240544 A CN201611240544 A CN 201611240544A CN 106822907 B CN106822907 B CN 106822907B
- Authority
- CN
- China
- Prior art keywords
- release
- racecadotril
- biphasic
- drug
- quick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ODUOJXZPIYUATO-UHFFFAOYSA-N 2-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]acetic acid (phenylmethyl) ester Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 229960002281 racecadotril Drugs 0.000 title claims abstract description 75
- 108700040249 racecadotril Proteins 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 103
- 229940079593 drug Drugs 0.000 claims abstract description 68
- 239000002245 particle Substances 0.000 claims abstract description 35
- 230000002051 biphasic effect Effects 0.000 claims abstract description 30
- 239000000796 flavoring agent Substances 0.000 claims abstract description 15
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 32
- 238000009472 formulation Methods 0.000 claims description 22
- 238000013268 sustained release Methods 0.000 claims description 22
- 239000012730 sustained-release form Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 21
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 239000001856 Ethyl cellulose Substances 0.000 claims description 11
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 11
- 229920001249 ethyl cellulose Polymers 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 229960003943 hypromellose Drugs 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000008369 fruit flavor Substances 0.000 claims 1
- 235000019658 bitter taste Nutrition 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 235000019640 taste Nutrition 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000000873 masking effect Effects 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229910021485 fumed silica Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- -1 2-acetylmercaptomethyl-1-oxo-3-phenylpropyl Chemical group 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of medicines, in particular to a racecadotril biphasic release preparation and a preparation method thereof. The preparation comprises medicine-containing particles with different release performances and the like, and the dosage of the components is as follows by mass percentage: 10-90% of slow-release medicine-containing particles, 10-90% of quick-release medicine-containing particles, 0.1-0.5% of lubricant and 0.1-1.0% of flavoring agent. The two-phase release preparation not only effectively covers the bitter taste of racecadotril, but also can ensure effective blood concentration, has simple preparation process and good reproducibility, and is suitable for industrial production.
Description
Technical Field
The invention relates to a racecadotril preparation, in particular to a dual-phase release preparation containing racecadotril and a preparation method thereof.
Technical Field
Diarrhea has been a gastrointestinal disease of great concern, with a high incidence, particularly in infants and the elderly. Compared with other antidiarrheal drugs, Racecadotril (Racecadotril) is an antidiarrheal drug with a new action mechanism, can selectively and reversibly inhibit enkephalinase, prolongs the physiological activity of endogenous enkephalin in the digestive tract, so as to inhibit excessive secretion of water and electrolytes to play the role of resisting diarrhea, has higher specificity antisecretory effect, is suitable for symptomatic treatment of various diarrhea, is easy to absorb, takes effect quickly, has small adverse reaction and high safety, and is particularly suitable for infant patients. Therefore, racecadotril is the most ideal anti-diarrhea drug at present and has great market potential.
Racecadotril is a compound existing in a racemic form, namely (+/-) N- (2-acetylmercaptomethyl-1-oxo-3-phenylpropyl) glycine benzyl ester (chemical structural formula is shown as the following). The drug was developed by Bioproject in france and first marketed in 1993 under the name Tiorfan in france for the treatment of acute diarrhea in adults.
The product is absorbed rapidly by oral administration, and is converted into active metabolite (+/-) -N- (1-oxygen-2-mercaptomethyl-3-phenylpropyl) glycine rapidly after entering into human body, the strength of inhibiting effect on enkephalinase is related to the dosage, and the clinically significant inhibiting effect on enkephalinase activity is achieved within 30 minutes; at the same time, the biological half-life period t of the medicine1/2About 3 hours, the metabolic elimination rate is relatively fast. Therefore, according to the in vivo metabolism characteristics of the medicament and better exertion of the clinical curative effect of the medicament, the medicament preparation is required to have the characteristic of quick medicament release at the early stage, can quickly release a certain amount of medicament in a short time and quickly achieve the effect; then slowly releases the drug, and maintains the drug concentration in the effective treatment range, namely, the drug release characteristics of two phases of early quick release and later slow release are required.
Meanwhile, racecadotril is a lipophilic compound which is almost insoluble in water and extremely bitter in taste, so that the pharmaceutical preparation has the suitable release characteristic and needs to effectively cover the bad taste, and the problems that the drugs are difficult to effectively release and the like are often encountered when the taste is covered by adopting the conventional coating and other technical methods.
Some patent reports are reported on the pharmaceutical preparation, but the pharmaceutical preparation mainly focuses on the dosage forms such as tablets and capsules. U.S. Pat. No. 6919093B 2 first discloses the use of a coating material Eudragit
The aqueous dispersion is granulated, and the bitter taste of racecadotril is covered by high-dose apricot essence and the like, but the method has high requirements on equipment, and the effects of covering the taste and effectively releasing the racecadotril are difficult to achieve simultaneously due to the fact that the method simultaneously covers the bitter taste of racecadotril
The complex composition of the emulsifier and the apricot flavor essence in the aqueous dispersion easily causes the problems of standard exceeding of impurities of finished products and the like; CN 102166197A discloses microencapsulation treatment of racecadotril with sodium alginate and other materials by a spraying method so as to achieve the taste masking effect, but the method has complex process and higher cost. Therefore, the preparation can meet the requirements of taste masking and effective drug release, is suitable for industrialized process prescription, and has important practical significance for developing racecadotril preparations.
Disclosure of Invention
Considering the dosage form selection of racecadotril in the aspect of medicine taking of paediatric patients and simultaneously considering the bitter taste and the characteristic requirements of medicine release of the racecadotril, the invention provides a biphase medicine release preparation taking racecadotril as a main medicine, aiming at not only effectively masking the taste, but also ensuring the effective blood concentration, and the invention adopts the technical scheme that:
a racecadotril-containing biphasic release preparation for treating diarrhea of pediatric patients comprises racecadotril which is composed of quick-release drug-containing particles and racecadotril slow-release drug-containing particles, and the preparation is an oral solid preparation.
The dual-phase release preparation containing racecadotril for treating diarrhea of pediatric patients further comprises a flavoring agent and a lubricant.
A dual-phase release preparation containing racecadotril for treating diarrhea of pediatric patients is an oral solid preparation consisting of quick-release drug-containing granules, slow-release drug-containing granules, flavoring agent and lubricant.
The quick-release drug-containing particles are racecadotril quick-release drug-containing particles; the slow-release drug-containing particles are racecadotril slow-release drug-containing particles.
The preparation method is characterized in that a conventional wet granulation technology is adopted, two common auxiliary materials of ethyl cellulose and hydroxypropyl methylcellulose are selected as adhesives, sustained-release drug-containing granules are prepared by utilizing the sustained-release characteristic of the ethyl cellulose, quick-release drug-containing granules are prepared by utilizing certain hydrophilicity of the hydroxypropyl methylcellulose, and then the two drug-containing granules with different drug release rates are mixed with proper lubricants, flavoring agents and the like according to a certain proportion to prepare the drug preparation with the double-phase drug release.
Wherein,
the sustained-release drug-containing granules are prepared by uniformly mixing racecadotril, a filling agent and a sustained-release material, preparing a soft material by a wet method, and then carrying out extrusion granulation, wherein the particle size of the obtained dry granules is controlled to be 0.42-0.71 mm. Wherein, the racecadotril accounts for 1.0 to 5.0 percent of the mass percent of the sustained-release granules, and the preferred mass percent is 3.0 percent; the mass percentage of the slow release material in the slow release particles is 0.5-10.0, preferably 2.5%; the filler can be one or more of sucrose, lactose, mannitol, sorbitol, microcrystalline cellulose, dextrin, and starch, preferably sucrose; the slow release material can be one or more of ethyl cellulose, acrylic resin, gelatin, sodium alginate, methyl cellulose, polyethylene glycol, and polyvinyl alcohol, preferably ethyl cellulose.
The quick-release drug-containing granules are prepared by uniformly mixing racecadotril, a filler and a quick-release material, preparing a soft material by a wet method, and preparing the quick-release granules by an extrusion preparation method, wherein the particle size of the obtained dry granules is controlled to be 0.42-0.71 mm. Wherein, the racecadotril accounts for 1.0 to 5.0 percent of the mass of the quick release particles, and the preferential mass is 3.0 percent; the mass percentage of the quick-release material in the quick-release particles is 0.5-10.0, preferably 1.5%; the filler can be one or more of sucrose, lactose, mannitol, sorbitol, microcrystalline cellulose, dextrin, and starch, preferably sucrose; the quick-release material can be one or more of hypromellose, hydroxypropyl cellulose, and polyvidone, preferably hypromellose.
The effective dose of racecadotril in the racecadotril biphasic release preparation is 5-50mg, preferably 30 mg; the mass ratio of the contained slow-release drug-containing particles to the quick-release drug-containing particles is 9:1 to 1:9, preferably 1-3:1, and most preferably 6: 4.
Then, the drug-containing granules are mixed with appropriate lubricants and flavoring agents, and packaged. Wherein the lubricant accounts for 0.1-2.0%, preferably 0.2% of the prescription amount; the flavoring agent accounts for 0.1-1.0%, preferably 0.3% of the prescription amount. The lubricant can be one or more selected from silicon dioxide, magnesium stearate and sodium stearyl fumarate, preferably silicon dioxide. The flavoring agent is selected from standard fruit essence such as peach essence, orange essence, etc.
Compared with the prior art, the invention has the advantages that:
(1) the hydroxypropyl methylcellulose with certain hydrophilicity is used for promoting the contact of the medicament and a dissolving medium so as to improve the medicament dissolution rate, achieve the quick-release medicament release effect, and also have the taste masking effect to a certain extent through granulation; the medicine is slowly released by utilizing the skeleton slow release effect of the water-insoluble ethyl cellulose, and meanwhile, the bitter taste of racecadotril is effectively covered by utilizing the wrapping treatment; the two modes are combined, so that the two-phase drug release is realized, and the bad taste of the racecadotril is effectively covered.
(2) The preparation method has the advantages of simple preparation process, good reproducibility and low requirement on equipment, can be completed by adopting the conventional wet granulation technology, and is suitable for industrialized production.
Drawings
FIG. 1 is an in vitro dissolution profile of the sustained release, immediate release and finished biphasic release formulations of example 2.
Detailed Description
The present invention is further illustrated by, but not limited to, the following examples.
Example 1:
prescription
(1) Prescription composition of medicine-containing granules
The preparation process of the medicine-containing granules comprises the following steps: pulverizing the medicine and sucrose to a certain particle size range, and mixing the medicine, sucrose, ethyl cellulose or hydroxypropyl methylcellulose in a wet granulating machine for 5 min; adding purified water to prepare a soft material; then placing the soft material on a 40-mesh screen of a swing type granulator for granulation; drying the formed granules in a vacuum drying oven at 50 +/-5 ℃ until the moisture content is less than 1%, and then granulating by using a 40-mesh sieve to obtain the finished product.
(2) Composition of racecadotril biphasic drug delivery preparation
The sustained-release drug-containing particles and the quick-release drug-containing particles, peach-flavor essence and fumed silica are placed in a mixer according to the proportion until the mixture is uniform, and each bag is subpackaged to obtain a final preparation product containing 3.0g and a main drug containing 30mg, namely the dual-phase release preparation containing racecadotril.
Example 2:
prescription
(1) Prescription composition of medicine-containing granules
The preparation process of the medicine-containing granules comprises the following steps: pulverizing the medicine and sucrose to a certain particle size range, and mixing the medicine, sucrose, ethyl cellulose or hydroxypropyl methylcellulose in a wet granulating machine for 5 min; adding purified water to prepare a soft material; then placing the soft material on a 40-mesh screen of a swing type granulator for granulation; drying the formed granules in a vacuum drying oven at 50 +/-5 ℃ until the moisture content is less than 1%, and then granulating by using a 40-mesh sieve to obtain the finished product.
(2) Composition of racecadotril biphasic drug delivery preparation
The sustained-release drug-containing particles and the quick-release drug-containing particles, peach-flavor essence and fumed silica are placed in a mixer according to the proportion until the mixture is uniform, and each bag is subpackaged to obtain a final preparation product containing 3.0g and a main drug containing 30mg, namely the dual-phase release preparation containing racecadotril.
Example 3:
prescription
(1) Prescription composition of medicine-containing granules
The preparation process of the medicine-containing granules comprises the following steps: pulverizing the medicine and sucrose to a certain particle size range, and mixing the medicine, sucrose, ethyl cellulose or hydroxypropyl methylcellulose in a wet granulating machine for 5 min; adding purified water to prepare a soft material; then placing the soft material on a 40-mesh screen of a swing type granulator for granulation; drying the formed granules in a vacuum drying oven at 50 +/-5 ℃ until the moisture content is less than 1%, and then granulating by using a 40-mesh sieve to obtain the finished product.
(2) Composition of racecadotril biphasic drug delivery preparation
The sustained-release drug-containing particles and the quick-release drug-containing particles, peach-flavor essence and fumed silica are placed in a mixer according to the proportion until the mixture is uniform, and each bag is subpackaged to obtain a final preparation product containing 3.0g and a main drug containing 30mg, namely the dual-phase release preparation containing racecadotril.
Example 4:
the results of the taste test of the different drug release granules and the finished product preparations obtained in examples 1-3 are shown in the following table.
Note: preferably 85-100, good 70-85, medium 55-70, and difference < 55.
As can be seen from the above table, in examples 1 to 3, after the racecadotril is granulated by using the water-insoluble ethyl cellulose as the sustained-release material, the bitter taste of the racecadotril can be effectively masked, and the taste masking effect is better as the proportion of the ethyl cellulose in the granulating prescription is increased; in the embodiments 1-3, hydrophilic hypromellose is used as a bonding agent to granulate the racecadotril, and a certain taste masking effect is also shown, but the material cannot well control the drug release and has a bitter characteristic, and the taste masking effect is more obvious along with the increase of the dosage proportion of the hypromellose. In examples 1-3, after mixing the drug-containing particles with different drug release rates according to a certain proportion,
under the action of flavoring agents and the like, the finished preparation has no bitter taste and bitter residue, good taste and easy acceptance by children. ()
Example 5:
the sustained-release drug-containing granules, the quick-release drug-containing granules, and the finished biphasic release preparation of example 2 were subjected to in vitro dissolution measurement, respectively. In vitro dissolution test conditions: medium 0.5% Sodium Dodecyl Sulfate (SDS); the rotating speed is 50 rpm; the temperature was 37.0 ℃. The dissolution results are shown in FIG. 1. As can be seen from the figure, the dissolution rate of the racecadotril sustained-release drug-containing granules in example 2 is only about 11% in 5min, and the granules are slowly released along with time, the dissolution end point of 120min is about 76%, and the sustained-release characteristic is provided; the 5min dissolution rate of the racecadotril quick-release medicine-containing granules is about 86 percent, the medicine release is rapid, and the medicine release end point is reached about 15min, which is close to complete release. After mixing the drug-containing granules with two different drug release characteristics according to a certain proportion, the initial dissolution rate of the finished preparation is about 40 percent, and then the drug-containing granules are gradually and slowly released along with time, thereby showing the obvious biphase drug release characteristics and obtaining the excellent dissolution effect.
In light of the present disclosure, those skilled in the art can utilize the present invention to its fullest extent. The preferred embodiments described above are therefore to be considered in all respects as illustrative and not restrictive.
Claims (17)
1. A racecadotril biphasic release preparation is characterized in that the racecadotril biphasic release preparation comprises racecadotril quick-release drug-containing granules and racecadotril sustained-release drug-containing granules, and the preparation is an oral solid preparation; the quick-release drug-containing particles are composed of racecadotril, a filler and a quick-release material, and the quick-release material of the quick-release drug-containing particles is hypromellose; the slow-release drug-containing granules consist of racecadotril, a filling agent and a slow-release material, wherein the slow-release material of the slow-release drug-containing granules is ethyl cellulose; the quick-release medicine-containing granules comprise the following components in percentage by mass: 1.0-5.0% of racecadotril and 0.5-10.0% of quick-release material; the sustained-release drug-containing granules comprise the following components in percentage by mass: 1.0-5.0% of racecadotril and 0.5-10.0% of slow-release material; the mass ratio of the slow-release drug-containing particles to the quick-release drug-containing particles is 1-3: 1.
2. The racecadotril biphasic release formulation of claim 1, characterized in that the formulation is an oral solid formulation consisting of immediate release drug-containing granules, sustained release drug-containing granules, flavoring agent, and lubricant.
3. A racecadotril biphasic release formulation according to claim 1 or 2, characterized in that: the filler of the quick-release medicine-containing granules is one or more of sucrose, lactose, mannitol, sorbitol, microcrystalline cellulose, dextrin and starch.
4. A racecadotril biphasic release formulation according to claim 3, characterized in that: the filler of the quick-release medicine-containing particles is sucrose.
5. A racecadotril biphasic release formulation according to claim 1 or 2, characterized in that: the filler of the sustained-release drug-containing granules is one or more of sucrose, lactose, mannitol, sorbitol, microcrystalline cellulose, dextrin and starch.
6. The racecadotril biphasic release formulation of claim 5, wherein: the filler of the sustained-release drug-containing particles is sucrose.
7. The racecadotril biphasic release formulation according to claim 2, characterized in that the flavoring agent is a standard fruit flavor.
8. A racecadotril biphasic release formulation according to claim 2, characterized in that the lubricant is one or more of silicon dioxide, magnesium stearate, sodium stearyl fumarate.
9. The racecadotril biphasic release formulation according to claim 8, characterized in that the lubricant is silicon dioxide.
10. A racecadotril biphasic release formulation according to claim 1 or 2, characterized in that the effective dose of racecadotril per racecadotril biphasic release formulation is between 5 and 50 mg.
11. A racecadotril biphasic release formulation according to claim 10, wherein the effective dose of racecadotril is 30mg per racecadotril biphasic release formulation.
12. The racecadotril biphasic release formulation of claim 1, characterized in that the mass ratio of the sustained-release drug-containing particles to the immediate-release drug-containing particles is 6: 4.
13. The racecadotril biphasic release formulation of claim 1, characterized in that the immediate release drug-containing granules comprise the following components in percentage by mass: 3.0 percent of racecadotril and 1.5 percent of quick-release material.
14. The racecadotril biphasic release preparation according to claim 1, characterized in that the sustained-release drug-containing granules comprise the following components in percentage by mass: 3.0 percent of racecadotril and 2.5 percent of slow release material.
15. A racecadotril biphasic release formulation according to claim 7, characterised in that the flavouring agent is present in an amount of 0.1-1.0% by mass of the total biphasic formulation.
16. The racecadotril biphasic release formulation of claim 8, wherein the lubricant comprises 0.1-2.0% by weight of the total biphasic formulation.
17. A process for the preparation of a racecadotril biphasic release formulation according to any one of claims 1-16, characterised in that it comprises the following steps: uniformly mixing racecadotril, filler, quick-release material or sustained-release material, making soft material by wet method, and preparing quick-release drug-containing granule or sustained-release drug-containing granule by extrusion granulation, wherein the particle diameter of the drug-containing granule is controlled at 0.42-0.71 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611240544.0A CN106822907B (en) | 2016-12-29 | 2016-12-29 | Two-phase release preparation containing racecadotril and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611240544.0A CN106822907B (en) | 2016-12-29 | 2016-12-29 | Two-phase release preparation containing racecadotril and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822907A CN106822907A (en) | 2017-06-13 |
| CN106822907B true CN106822907B (en) | 2021-02-09 |
Family
ID=59113598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611240544.0A Active CN106822907B (en) | 2016-12-29 | 2016-12-29 | Two-phase release preparation containing racecadotril and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822907B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108740677A (en) * | 2018-06-22 | 2018-11-06 | 化州化橘红药材发展有限公司 | A kind of Exocarpium Citri Grandis slow-release solid beverage and preparation method thereof |
| GB2586201B (en) * | 2019-05-14 | 2023-05-24 | Orbit Pharmaceuticals | A stable powder formulation of racecadotril |
| CN112220757B (en) * | 2020-10-16 | 2022-05-27 | 重庆市义力医药科技有限公司 | Nicotine particle composition, preparation method and preparation device thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2900823B1 (en) * | 2006-05-15 | 2009-02-13 | Bioprojet Soc Civ Ile | NEW FORM OF ADMINISTRATION OF RACECADOTRIL. |
| CN102091051B (en) * | 2009-12-14 | 2013-01-23 | 北京科信必成医药科技发展有限公司 | Allopurinol dual-release preparation and preparation method thereof |
| CN104224724A (en) * | 2013-06-08 | 2014-12-24 | 北京韩美药品有限公司 | Racecadotril granules and preparation technology thereof |
-
2016
- 2016-12-29 CN CN201611240544.0A patent/CN106822907B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| "Compressed mini-tablets as a biphasic delivery system";Carla M. Lopes et al.;《International Journal of Pharmaceutics》;20060606;第323卷;第93-100页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822907A (en) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2937376B2 (en) | Sustained-release pharmaceutical composition | |
| JP5065548B2 (en) | Galen composition containing an opioid antagonist | |
| KR880002673B1 (en) | Analgesic capsule | |
| US20030175355A1 (en) | Fast melt multiparticulate formulations for oral delivery | |
| JPH0122245B2 (en) | ||
| CN1123142A (en) | Fluoxetine pharmaceutical formulations | |
| US20110268808A1 (en) | Dual-release pharmaceutical suspension | |
| JPS63196511A (en) | Swellable pellets | |
| JPH08503482A (en) | Cimetidine granules coated with partially hydrogenated vegetable oil | |
| JPH072635B2 (en) | Novel pharmaceutical preparation and method for producing the same | |
| JP2009543791A (en) | Multiparticulate formulations having immediate release and sustained release forms of tramadol | |
| CN107811994B (en) | Xilipapage pH-dependent time-lag colon targeted pellet and preparation method thereof | |
| CN103315965A (en) | Oral solid granule suitable for infants and children, and preparation method thereof | |
| JP2007517011A (en) | Multiparticulate formulation for oral delivery | |
| JP2010524926A (en) | High dose composition of ursodeoxycholic acid | |
| JP2004507487A (en) | Intestinal disease drug | |
| CN106822907B (en) | Two-phase release preparation containing racecadotril and preparation method thereof | |
| CN102151247A (en) | Dry powder formulation comprising racecadotril | |
| TW200528092A (en) | Multiparticulate o-desmethylvenlafaxine salts and uses thereof | |
| JP3221891B2 (en) | Rotary granulation and taste-masking coating for the preparation of chewable pharmaceutical tablets | |
| JP2000500477A (en) | Immediate release pharmaceutical composition | |
| JP4848101B2 (en) | Sustained release micropellet | |
| CN105832671A (en) | Dry suspension for controlled-release of medicine and preparation method of dry suspension | |
| CN108030770A (en) | Controllable dry suspensoid agent of drug release containing drug-resin complex and preparation method thereof | |
| CN105496967B (en) | Ranitidine hydrochloride controlled release dry suspensoid agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |